Mainstream

FibroGen raises China sale guidance to $210M, extends cash runway into 2028 as Phase II prostate cancer trial advances

FibroGen raises China sale guidance to $210M, extends cash runway into 2028 as Phase II prostate cancer trial advances

Post ContentfgenRead More

You might also be interested in reading Opendoor Technologies reports insider transaction worth ~$2M.

August 12, 2025
In Mainstream